(131) Feasibility of telehealth spirometry for patients with cystic fibrosis in a regional setting

Background: Telemedicine has flourished during the covid-19 pandemic. There is an increasing interest in performing spirometry at home, as part of a telehealth program, especially in cystic fibrosis (CF), to follow the course of the disease. However, it is unclear whether the results of home spirometry are comparable with the in-clinic performed spirometry in terms of quality and accuracy. This study aimed to evaluate the feasibility and measurement quality of telehealth spirometry assessments for patients with CF living in a regional setting.

Methods: Patients with acceptable hardware at home were provided with a flow sensor portable spirometer (Spirobank Smart) compatible with ATS/ERS 2019 standards for volume accuracy. They performed spirometry during "home admissions" or ongoing home monitoring for one year over the COVID-19 pandemic (January 2021 to January 2022). At the end of each session, the family forwarded the data to the CF Centre.

Results: Twenty-nine patients with a median age of 17.4 years (6.7 to 34 years), 58% of females were evaluated (mean baseline FEV1pp 79.8 (21.4). According to the American Thoracic Society/European Respiratory Society criteria, they performed successful spirometry in 320 of 430 (74.5%) attempted sessions. The median distance between the subject's home and the hospital was 124 km (range 49-418 km), equating to a median travel time saving of 1.5 hours per hospital visit.

Conclusions: Home-based telehealth spirometry is feasible among patients with CF and can support the CF team for ongoing outpatient monitoring.

Acknowledgements:

References: 1. Avdimiretz N, Wilson D, Grasemann H. Comparison of a handheld turbine spirometer to conventional spirometry in children with cystic fibrosis. Pediatr Pulmonol. 2020 Jun;55(6):1394-1399. doi: 10.1002/ppul.24743.
2. Paynter A, Khan U, Heltshe SL, Goss CH, Lechtzin N, Hamblett NM. A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis. J Cyst Fibros. 2022 Jan;21(1):78-83. doi: 10.1016/j.jcf.2021.08.013.
3. Exarchos KP, Gogali A, Sioutkou A, Chronis C, Peristeri S, Kostikas K. Validation of the portable Bluetooth® Air Next spirometer in patients with different respiratory diseases. Respir Res. 2020 Apr 6;21(1):79.